Comparative Effects of Telmisartan and Eprosartan on Insulin Sensitivity in the Treatment of Overweight Hypertensive Patients

Abstract

The aim of this study was to compare the effect of telmisartan and eprosartan on insulin sensitivity in overweight hypertensive patients. Fifty overweight (BMI≥25 and <30 kg/m²) outpatients, aged 41–65 years, with mild to moderate hypertension [systolic blood pressure (SBP) >140 and diastolic blood pressure (DBP) ≥90 and ≤110 mmHg], after a 4-week placebo period, were randomized to receive telmisartan 80 mg or eprosartan 600 mg for 8 weeks. Following another 4-week placebo period, patients were crossed to the alternative regimen for further 8 weeks. At the end of each placebo and active treatment period, blood pressure (BP), insulin sensitivity (by euglycemic hyperinsulinemic clamp), fasting plasma glucose (FPG), insulin (FPI), total cholesterol (TC), LDL-C, HDL-C, and triglycerides (Tg) were evaluated. Insulin sensitivity was expressed as the amount of glucose infused during the last 30 min (glucose infusion rate, GIR) in μmol/min/kg. Both telmisartan and eprosartan significantly reduced SBP/DBP values (by a mean of 19.4/13.3 mmHg and 17.9/12.1 mmHg respectively, all p<0.001 vs. placebo), with no significant difference between the two treatments. GIR was significantly increased by telmisartan (2.25±0.61 μmol/min/kg, p<0.05 vs. placebo) but not by eprosartan (0.25±0.14 μmol/min/kg, p=ns), the difference between the two drugs being statistically significant (p<0.02). No change in FPG, FPI, HDL-C, and Tg was observed with either treatment. Telmisartan significantly reduced TC (−9.9 mg/dl, −5%, p<0.04 vs. placebo) and LDL-C (−8.8 mg/dl, −7%, p<0.03 vs. placebo), whereas eprosartan did not influence them. These findings indicate a superiority regarding an improvement of insulin sensitivity and plasma lipid profile in overweight hypertensives by telmisartan as compared to eprosartan, possibly related to the selective stimulating PPAR-γ property of telmisartan.

sartans - hyperinsulinemic clamp - hypertension - AT 1 blockers - insulin resistance - body weight

References

• 1 Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dieta WH. The disease burden associated with overweight and obesity.  JAMA. 1999;  282 1523-1529
• 2 Brown CD, Higgins M, Donato KA. Body mass index and the prevalence of hypertension and dyslipidemia.  Obes Res. 2000;  8 605-619
• 3 Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH. American Heart Association; Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism . Obesity and cardiovascular disease: pathophysiology, evaluation and effect of weight loss. An update of the 1997 American Heart Association Scientific Statement on obesity and heart disease from the Obesity Committee of the Obesity Committee of the Council on Nutrition, Physical Activity and Metabolism.  Circulation. 2006;  113 898-918
• 4 Richards RJ, Thakur V, Reisin E. Obesity-related hypertension: its physiological basis and pharmacological approaches to its treatment.  J Hum Hypertens. 1996;  10 ((Suppl 3)) S59-S64
• 5 Rocchini AP. Obesity hypertension.  Am J Hypertens. 2002;  15 50S-52S
• 6 Dentali F, Sharma AM, Douketis JD. Management of hypertension in overweight and obese patients: a practical guide for clinicians.  Curr Hypertens Res. 2005;  7 330-336
• 7 Wenzel UO, Krebs C. Treatment of arterial hypertension in obese patients.  Contrib Nephrol. 2006;  151 230-242
• 8 Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. LIFE Study Group . Cardiovascular morbidity and mortality in the Losartan Intervention For End-point reduction in hypertension study (LIFE): a randomised trial against atenolol.  Lancet. 2002;  359 995-1003
• 9 Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the Renin Angiotensin System.  Drugs. 2004;  64 2537-2565
• 10 Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, Hua T, Laragh JH, McInnes GT, Mitchell L, Plat F, Schork MA, Smith B, Zanchetti A. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial.  Lancet. 2004;  363 2049-2051
• 11 Ostergren J. Renin-angiotensin system blockade in the prevention of diabetes.  Diabetes Res Clin Pract. 2007;  73 ((Suppl 3)) S13-S21
• 12 Shiuchi T, Cui TX, Wu L, Nakagami H, Takeda-Matsubara Y, Iwai M, Horiuchi M. ACE-inhibitor improve insulin resistance in diabetic mouse via bradykinin and NO.  Hypertension. 2002;  40 329-334
• 13 Kurtz TW, Pravenec M. Molecule-specific effects of angiotensin II-receptor blockers independent of the renin-angiotensin system.  Am J Hypertens. 2008;  21 852-859
• 14 Kintscher U, Foryst-Ludwig A, Unger T. Inhibitin angiotensin type 1 receptors as a target for diabetes.  Expert Opin Ther Targets. 2008;  12 1257-1263
• 15 Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type-1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.  Circulation. 2004;  109 2054-2057
• 16 Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B, Kintscher U. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity.  Diabetes. 2005;  54 3442-3452
• 17 Erbe DV, Gartrell K, Zhang YL, Suri V, Kirincich SJ, Will S, Perreault M, Wang S, Tobin JF. Molecular activation of PPAR- by angiotensin II type-1 receptor antagonists.  Vascular Pharmacology. 2006;  45 154-162
• 18 Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomised, double-blind, placebo-controlled 12-month study.  Hypertens Res. 2004;  27 457-464
• 19 Miura Y, Yamamoto N, Tsunekawa S, Taguchi S, Eguchi Y, Ozaki N, Oiso Y. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences.  Diabetes Care. 2005;  28 757-758
• 20 Honjo S, Nichi Y, Wada Y, Hamamoto Y, Koshiyama H. Possible beneficial effect of telmisartan on glycemic control in diabetic subjects.  Diabetes Care. 2005;  28 498
• 21 Vitale C, Mercuro G, Castiglioni C, Cornoldi A, Tulli A, Fini M, Volterrani M, Rosano GM. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome.  Cardiovasc Diabetol. 2005;  4 6
• 22 Derosa G, Cicero AF, D’Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Ferrari I, Gravina A, Fogari R. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-α.  Hypertens Res. 2006;  29 849-856
• 23 Negro R, Formoso G, Hassan H. The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin-resistant, hypertensive patients.  J Endocrinol Invest. 2006;  29 957-961
• 24 Bahadir O, Uzunlulu M, Oguz A, Bahadir MA. Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome.  Hypertens Res. 2007;  30 49-53
• 25 Mori Y, Itoh Y, Tajima N. Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes.  Adv Ther. 2007;  24 146-153
• 26 Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension.  Drugs. 2001;  61 1501-1529
• 27 Plosker GL, Foster RH. Eprosartan: a review of its use in the management of hypertension.  Drugs. 2000;  60 177-201
• 28 De Fronzo RA, Tobin JA, Andres B. Glucose clamp technique, a method for quantifying insulin secretion and resistance.  Am J Physiol. 1979;  237 214-223
• 29 Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance in essential hypertension.  N Engl J Med. 1987;  317 350-357
• 30 European Diabetes Policy Group. . A desktop guide to type 2 diabetes mellitus.  Diab Med. 1999;  16 716-730
• 31 Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients.  Diabetologia. 1972;  8 260-266
• 32 Klose S, Borner K. Enzymatische Bestimmung des Gesamtcholesterins mit dem Greiner Selective Analyzer (GSA II).  J Clin Chem Clin Biochem. 1978;  15 121-130
• 33 Wahlefeld AW. Triglycerides determination after enzymatic hydrolysis. In: Bermeyer HU (ed) Methods of Enzymatic Analysis, 2nd English ed. New York: Academic Press Inc. 1974: 18-31
• 34 Havel RJ, Edr HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum.  J Clin Invest. 1955;  34 1345-1353
• 35 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge.  Clin Chem. 1972;  18 499-502
• 36 Senn SJ. Cross-over trials in clinical research. New York: Wiley 1993
• 37 Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group.  Lancet. 1998;  351 1755-1762
• 38 Heart Outcomes Prevention Evaluation Study (HOPE) Investigators. . Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients.  N Engl J Med. 2000;  342 145-153
• 39 Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function.  Best Pract Res Clin Endocrinol Metab. 2003;  17 305-322
• 40 Motley ED, Eguchi K, Gardner, Hicks AL, Reynolds CM, Frank GD, Mifune M, Ohba M, Eguchi S. Insulin-induced Akt activation is inhibited by angiotensin II in the vasculature through protein kinase C-alpha.  Hypertension. 2003;  41 775-780
• 41 Picard F, Auwerx J. PPAR-gamma and glucose homeostasis.  Annu Rev Nutr. 2002;  22 167-197
• 42 Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, VanderMaelen C, Voigt T, Weber M, Yoon BW. PRoFESS Study Group . Telmisartan to prevent recurrent stroke and cardiovascular events.  N Engl J Med. 2008;  359 1225-1237
• 43 Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, Zinman B. HOPE Study Investigators . Ramipril and the development of diabetes.  JAMA. 2001;  286 1882-1885
• 44 Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis.  Lancet. 2007;  369 201-207
• 45 The DREAM Trial Investigators. . Effect of ramipril on the incidence of diabetes.  N Engl J Med. 2006;  355 1551-1562
• 46 Mann JF, Schmieder RE, Dyal L, McQueen MJ, Schumacher H, Pogue J, Wang X, Probstfield JL, Avezum A, Cardona-Munoz E, Dagenais GR, Diaz R, Fodor G, Maillon JM, Rydén L, Yu CM, Teo KK, Yusuf S. for the TRANSCEND (Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease) Investigators . Effect of Telmisartan on Renal Outcomes: A Randomized Trial.  Ann Intern Med. 2009;  151 1-10
• 47 Yki-Jarvinen H. Thiazolidinediones.  N Engl J Med. 2004;  351 1106-1118
• 48 Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.  J Hum Hypertens. 2000;  14 S73-S86
• 49 Janke J, Schupp M, Engeli S, Gorzelniak K, Boschmann M, Sauma L, Nystrom FH, Jordan J, Luft FC, Sharma AM. Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation.  J Hypertens. 2006;  24 1809-1816
• 50 Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation.  Biochim Biophys Acta. 1996;  1302 93-109
• 51 Clemenz M, Frost N, Schupp M, Caron S, Foryst-Ludwig A, Böhm C, Hartge M, Gust R, Staels B, Unger T, Kintscher U. Liver-specific PPARα-target gene regulation by the angiotensin type 1 receptor blocker telmisartan.  Diabetes. 2008;  57 1405-1413
• 52 Marx N, Kehrle B, Kohlhammer K, Grüb M, Koenig W, Hombach V, Libby P, Plutzky J. PPAR activators as anti-inflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis.  Circ Res. 2002;  90 703-710
• 53 Walcher D, Hess K, Heinz P, Petscher K, Vasic D, Kintscher U, Clemenz M, Hartge M, Raps K, Hombach V, Marx N. Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-gamma.  Hypertension. 2008;  51 259-266
• 54 Scalera F, Martens-Lobenhoffen J, Buckowska A, Lendeckel U, Tager M, Bode-Boger SM. Effect of telmisartan on nitric oxide-asymmetrical dimethylarginine system, role of angiotensin II type 1 receptor and peroxisome proliferator activated receptor gamma signalling during endothelial aging.  Hypertension. 2008;  51 696-703

Correspondence